{"filings":[{"id":1415960,"accession_number":"0001493152-26-031918","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-07-02T20:30:31+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharmaceuticals appoints Danina Fisher and Gary S. Stetz, II to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Danina Fisher and Gary S. Stetz, II appointed as directors effective July 1, 2026.","Gary S. Stetz, II is the son of Gary Stetz, the Interim CEO.","No arrangements or understandings with any other person regarding their selection as directors.","No family relationships exist between the new directors except the father-son relationship noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111396,"accession_number":"0001493152-26-029085","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-06-17T20:15:20+00:00","items":["5.07"],"status":"ready","headline":"Hepion shareholders approve 40x increase in equity plan shares to 8M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Stetz, V. LoPriore, Purcell, Appajosyula, C. LoPriore with ~13.5M votes each.","Ratified Grassi & Co. as auditors for FY2026: 18.1M for, 117K against, 223K abstain.","Approved amendment to 2023 equity plan, increasing shares from 200K to 8M: 13.4M for, 209K against.","Broker non-votes totaled 4.8M on director election and equity plan proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93859,"accession_number":"0001493152-26-018575","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.","Gross proceeds from the private placement were $700,000, and the offering closed on the same date.","The shares were issued in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.","Gary Stetz, Interim CEO, signed the 8-K filing on behalf of Hepion Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93858,"accession_number":"0001493152-26-016557","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.","Lbiati resigned as CEO on March 16, 2026, and as director on April 13, 2026.","Gary Stetz serves as Interim CEO effective from the separation date.","Separation includes a general release and confidentiality covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105818,"accession_number":"0001493152-26-011222","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.","Board appointed Gary Stetz as interim CEO and director; Vincent LoPriore as Executive Chairman.","Sireesh Appajosyula and Chase LoPriore also appointed to the board of directors.","No family relationships or arrangements between new appointees and other officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105817,"accession_number":"0001493152-26-008650","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.","Assay detects mutant circulating tumor RNA (ctRNA) for early HCC diagnosis in high-risk cirrhosis patients.","Complements Hepion's mSEPT9 PCR assay; strategic shift to liquid biopsy diagnostics.","Global liquid biopsy market ~$10B; plans CLIA lab partnerships and eventual FDA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105816,"accession_number":"0001493152-26-002428","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.","Annual base salary $350,000; $50,000 deferred until equity financing ≥$3M, termination, or change of control.","Annual cash bonus target 35% of base salary based on Board-set goals.","Change-of-control bonus: 3% of enterprise value if ≥$5M.","Severance: 6 months base plus bonus upon termination without cause or good reason; equity acceleration provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156257,"accession_number":"0001641172-25-017037","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.","Kaouthar Lbiati assumes role of Interim Chief Financial Officer as of the filing date.","No permanent successor has been announced; company is a clinical-stage biotech (HEPA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156256,"accession_number":"0001641172-25-014858","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion shareholders reject reverse stock split amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.","All four director nominees (Brancaccio, Block, Lbiati, Purcell) elected despite majority of votes withheld.","Ratification of Grassi & Co. as auditors passed with 4.76M for vs 1.17M against.","Advisory say-on-pay failed with 162K for, 337K against.","Only 10.9M shares outstanding; broker non-votes totaled 5.46M on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156255,"accession_number":"0001641172-25-014320","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.","Initial term of 3 months; annual base salary $350,000 with $50,000 deferred until equity financing ≥$3M or departure.","Performance bonus eligible at 35% of base salary upon milestones; pro-rated bonus if terminated without cause before term end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156254,"accession_number":"0001641172-25-013048","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.","Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.","Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156253,"accession_number":"0001641172-25-009744","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Hepion delisted from Nasdaq; pivots to diagnostics via New Day license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.","Expects common stock to trade on OTC Markets under symbol HEPA after suspension.","Entered license agreement with New Day Diagnostics on May 9, 2025, for diagnostic tests (celiac, respiratory multiplex, H. pylori, HCC).","Celiac, respiratory, and H. pylori tests have CE marks and are eligible for sale in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156252,"accession_number":"0001641172-25-008761","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Hepion in-licenses diagnostic tests from New Day Diagnostics for $0.725M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["In-licensed celiac, respiratory multiplex (COVID/flu A/B/RSV), H. pylori, and HCC tests; three have CE marks for EU sale.","Upfront consideration: $525k cash + $200k in unregistered common stock to New Day Diagnostics.","Milestone payments up to $17.15M on regulatory, sales, and reimbursement milestones; royalties in upper single to low double digits.","Binding LOI is effective immediately; termination requires mutual consent. Parties to execute definitive license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156251,"accession_number":"0001641172-25-005241","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.","Nasdaq Hearings Panel will consider this matter at hearing scheduled for April 29, 2025.","Company intends to present its views on the additional deficiency at the Panel hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156250,"accession_number":"0001641172-25-002775","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K/A","filed_at":"2025-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hepion files amended balance sheet to correct warrant accounting; $6.14M warrant liability recorded","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 8-K/A filed to correct accounting for Series A and B warrants issued in Jan 2025 offering.","Unaudited balance sheet as of Jan 31, 2025 shows cash $5.22M and total assets $6.36M.","Derivative financial instruments-warrants liability of $6.14M recorded, exceeding total stockholders' equity of ($23,916).","Prepaid expenses $1.14M; accounts payable $220K; accrued expenses $23.7K.","No other changes to original 8-K filed March 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174714,"accession_number":"0001493152-25-011038","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hepion receives Nasdaq delisting notice as bid price falls below $0.10 for 10 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $0.10 for 10 consecutive business days triggering the Low Priced Stocks Rule.","If no appeal by March 25 and $20,000 fee, delisting from Nasdaq Capital Market starts March 27, 2025.","Company intends to appeal but cannot guarantee success in continuing listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174713,"accession_number":"0001493152-25-010921","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals implements 1-for-50 reverse stock split effective March 17, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Every 50 pre-split shares reclassified into 1 share; par value unchanged at $0.0001.","Authorized shares of common and preferred stock remain unchanged.","No fractional shares issued; stockholders receive cash in lieu of fractions.","Outstanding options and warrants adjusted proportionately; exercise prices increased.","New CUSIP number is 426897401; stock continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174712,"accession_number":"0001493152-25-009686","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.","Ratification of Grassi & Co. as auditor for FY2024 approved: 2,974,800 For, 603,560 Against.","Advisory say-on-pay approved: 1,419,035 For, 853,863 Against, 244,418 Abstentions.","Issuance of shares upon Series A and B Warrants approved: 1,720,659 For, 793,847 Against.","Reverse stock split amendment approved (2,685,475 For); board to set ratio (1:10-1:50) and timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174711,"accession_number":"0001493152-25-009075","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals provides unaudited balance sheet as of Jan 31, 2025; cash of $5.36M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents of $5.36M as of January 31, 2025.","Total assets of $6.5M, total liabilities of $0.55M.","Stockholders' equity of $5.95M, accumulated deficit of $238M.","No revenue or operational update provided; balance sheet only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174710,"accession_number":"0001493152-25-002377","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hepion Pharma receives Nasdaq delisting notice for failure to hold annual meeting; 45 days to submit compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated January 14, 2025 from Nasdaq for failing to hold annual shareholders' meeting within 12 months of fiscal year end.","Company has 45 days to submit a plan to regain compliance; intends to do so.","If plan accepted, Nasdaq may grant extension to June 30, 2025; if not, company can appeal.","Common stock (HEPA) continues trading on Nasdaq Capital Market during the process.","No assurance that listing will be maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191667,"accession_number":"0001493152-24-049561","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Hepion terminates merger with Pharma Two B; special meeting cancelled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger Agreement with Pharma Two B Ltd. terminated mutually on Dec 10, 2024.","No termination fee payable by either party.","Special stockholders meeting scheduled for Dec 12, 2024 cancelled; proposals withdrawn.","Nasdaq would not exclude historical losses from burn-rate calculation, leading to termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191666,"accession_number":"0001493152-24-047182","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hepion Pharma receives Nasdaq delisting notice due to stockholder deficit and failure to meet listing alternatives","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.","Company fails to meet alternatives: $35M market value or $500K net income in recent fiscal years.","Nasdaq gives 45 days to submit a compliance plan; extension of up to 180 days possible.","Common stock (HEPA) continues trading on Nasdaq Capital Market while cure process is pending.","No assurance that listing will be maintained; potential for hearing panel appeal if plan rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208135,"accession_number":"0001493152-24-035076","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hepion Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Sept. 3, 2024; bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until March 3, 2025, to regain compliance.","To regain compliance, closing bid must be ≥$1.00 for at least 10 consecutive business days.","If not compliant, may qualify for a second 180-day period; otherwise Nasdaq will delist.","Common stock continues trading on Nasdaq under symbol HEPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208134,"accession_number":"0001493152-24-030495","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.","John Brancaccio, executive chairman, appointed interim CEO and CFO effective August 6.","Company is a clinical-stage biotech (HEPA) with no named permanent successor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208133,"accession_number":"0001493152-24-028637","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals enters definitive merger agreement with Pharma Two B Ltd., expects Q4 2024 close","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.","Concurrent $2.9M note sale (SPA) at 116% of principal; purchasers also receive up to 19.99% of HEPA outstanding shares.","Closing expected Q4 2024, subject to stockholder approvals, Nasdaq listing, IIA approval, and at least $8.6M cash from SPA.","Certain Hepion stockholders entered support agreements (covering ~0.025% of shares) and 180-day lock-up agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244851,"accession_number":"0001493152-24-009028","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion appoints Michael Purcell to board as Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Purcell appointed as director of Hepion Pharmaceuticals on March 5, 2024.","Purcell named Chair of Audit Committee and member of Compensation and Corporate Governance/Nominations Committees.","No departures reported; Purcell fills a board vacancy.","Appointment effective immediately upon board vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244850,"accession_number":"0001493152-24-007222","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chairman Gary Jacob resigns from Hepion board; John Brancaccio appointed Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gary Jacob resigned as Chairman and from the Board on February 20, 2024, for personal reasons.","Board appointed John Brancaccio as new Chairman effective immediately.","John Cavan continues as Interim CEO and CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244849,"accession_number":"0001104659-24-024738","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Hepion raises $2.06M via warrant inducement, reduces exercise prices and issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 980,393 Series B warrants will exercise at reduced price of $2.10/share, raising ~$2.06M gross proceeds.","As inducement, Company reduces Series A warrant exercise price to $1.91 (from $4.85) and extends expiration to Feb 2029.","Company issues new Series B-1 and B-2 warrants to purchase up to 735,295 shares each at $1.91.","Engaged A.G.P./Alliance Global Partners as financial advisor; cash fee of 7% of gross proceeds.","Net proceeds to be used for general working capital and corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244848,"accession_number":"0001104659-24-011616","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharma Director Anand Reddi resigns from board effective Feb 7, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anand Reddi resigned from Board of Directors on Feb 7, 2024.","He served as Chairman of Compensation Committee and member of Governance/Nominations Committee.","No successor appointed or reason for resignation disclosed.","Company did not provide any further details or comments on the departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244847,"accession_number":"0001104659-24-000860","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.","BDO reports for FY 2021 and 2022 contained going-concern explanatory paragraph due to recurring losses and accumulated deficit.","Material weaknesses in internal control over financial reporting identified in prior annual and quarterly reports.","No disagreements with BDO on accounting principles or audit scope during the past two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262294,"accession_number":"0001104659-23-124182","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.","John Cavan (CFO) appointed interim CEO; Dr. Peter Wijngaard also resigns from board.","Board approves strategic restructuring to reduce operating costs by ~60%, with one-time charge of $400-$800K in Q4 2023.","Company to explore strategic alternatives including M&A, licensing, or sale; 131 patients in Phase 2b NASH trial.","Cash runway extended into Q2 2025; will add trial patients only if fully funded or strategic deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262293,"accession_number":"0001104659-23-106030","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.","Series A and B warrants to buy up to 980,393 shares each at $4.85; Series A expires in 5 yrs, Series B in 1.5 yrs.","Closing expected on or about Oct 3, 2023; A.G.P./Alliance Global Partners as placement agent.","Net proceeds intended for clinical development and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279488,"accession_number":"0001104659-23-098668","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion CMO Todd Hobbs resigns; Stephen Harrison appointed Consultant Medical Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Todd Hobbs resigned as CMO effective September 29, 2023; resignation not due to any disagreement with the Company.","Company appointed Dr. Stephen Harrison as Consultant Medical Director; he chairs the Scientific Advisory Board.","Dr. Harrison previously served as Consultant Medical Director from Oct 2019 to Feb 2021; leads Pinnacle Clinical Research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279487,"accession_number":"0001104659-23-083425","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hepion provides corporate presentation; no material new financial or clinical data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.","Phase 2a HCC trial pending; rencofilstat tested in over 425 subjects to date.","Cash of $43.0M as of March 31, 2023; IP extends to at least 2031 with PTE.","Core team previously developed voclosporin (Lupkynis) for lupus nephritis.","Presentation details pipeline, finance, and management; no new clinical results disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279486,"accession_number":"0001104659-23-083084","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.","Commission of 3.0% of gross proceeds paid to Cantor; Company provides customary indemnification.","Shares sold under existing effective shelf registration statement (File No. 333-254996).","No obligation to sell; offering terminates upon full issuance or termination of agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297887,"accession_number":"0001104659-23-073836","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion Pharma stockholders elect all director nominees, ratify BDO, approve equity plan, pass say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; votes For ranged from 15.7M (Jacob) to 20.7M (Wijngaard).","Ratification of BDO USA as auditors passed with 32.5M For, 8.3M Against, 0.8M abstain.","2023 Omnibus Equity Incentive Plan approved with 14.4M For, 12.0M Against, 0.3M abstain.","Advisory say-on-pay proposal passed with 14.2M For, 12.2M Against, 0.4M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297886,"accession_number":"0001104659-23-063036","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Hepion Phase 2 ALTITUDE-NASH trial meets primary endpoint with rencofilstat 225 mg improving liver function","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).","61% of 225 mg arm achieved ≥2-point DSI improvement (p<0.05); RISK ACE reduced 1.2 events/100 pt-yrs (p<0.001).","Secondary endpoints: ALT ↓21.6%, AST ↓4.7%, ProC3 ↓9.6%, PIIINP ↓5.6%, ELF score ↓2.5% at 225 mg (all p<0.001).","Rencofilstat well tolerated; no drug-related SAEs; supports ongoing Phase 2b ASCEND-NASH paired biopsy trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297885,"accession_number":"0001104659-23-058529","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals effects 1-for-20 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20 effective 4:01pm ET May 10, 2023; split-adjusted trading begins May 11 under same symbol HEPA.","Post-split shares outstanding ~3.81M; CUSIP changed to 426897302.","Primary purpose is to meet Nasdaq minimum bid price requirement for continued listing.","Proportionate adjustments to equity awards and warrants; fractional shares rounded up to next whole share.","CEO states split comes ahead of expected Phase 2 ALTITUDE-NASH biomarker results for rencofilstat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336415,"accession_number":"0001104659-22-127475","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion shareholders approve reverse stock split; Board to set ratio 1:2 to 1:20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Dec 15, 2022; proposal to amend charter for reverse split approved.","Vote: 6,757,528,739 for, 3,262,017,173 against, 38,856,945 abstained; 0 broker non-votes.","Board authorized to select ratio between 1:2 and 1:20 within one year of meeting.","Proposal covers all outstanding common and preferred shares as of Nov 8, 2022 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336414,"accession_number":"0001104659-22-116082","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.","Each preferred share convertible into common at $1.00 per share (5% original issue discount).","Investors agreed to vote Series F in favor of reverse stock split; Series G votes mirror proportions.","Company filed certificates of designation and entered registration rights agreement for resale.","A.G.P./Alliance Global Partners acted as placement agent with $1M cash fee plus expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336413,"accession_number":"0001104659-22-109389","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.","Rencofilstat Phase 2b ASCEND-NASH (biopsy) and Phase 2 ALTITUDE-NASH (liver function) trials underway.","Upcoming Phase 2a HCC trial for rencofilstat in advanced hepatocellular carcinoma.","AI-POWR platform used to identify responders and companion diagnostic panel.","Rencofilstat shown safe/tolerated in >200 subjects; Phase 2a AMBITION study met primary endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353814,"accession_number":"0001104659-22-086685","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion shareholders reject authorized share increase from 120M to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal received 19,267,720 For, 27,847,827 Against, 254,176 Abstain; broker non-votes 1.","The amendment to the certificate of incorporation was not approved.","Meeting was previously adjourned to complete voting on this proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371644,"accession_number":"0001104659-22-075050","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Hepion appoints Anand Reddi and Kaouthar Lbiati to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 8; Reddi and Lbiati appointed independent directors effective June 27, 2022.","Each receives $50,000 annual cash retainer and option to purchase 60,000 shares of common stock.","Anand Reddi is VP at Adverum Biotechnologies; previously led international access at Gilead for HIV and hepatitis drugs.","Kaouthar Lbiati is VP at Cytovia Therapeutics; held global leadership roles at Amgen, GSK, and Sanofi.","Company is preparing rencofilstat for three Phase 2 trials in NASH and HCC and exploring partnering opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371643,"accession_number":"0001104659-22-074485","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion Pharma annual meeting: equity plan & say-on-pay fail; 3 directors face majority withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 3 (2022 Omnibus Equity Incentive Plan) failed: 11.0M for, 20.1M against.","Proposal 5 (say-on-pay) failed: 9.2M for, 21.6M against.","Directors Gary Jacob, John Brancaccio, and Timothy Block each received more withhold votes than for votes.","Proposal 4 (authorized share increase) adjourned to July 22, 2022 due to insufficient votes.","Proposal 2 (ratify BDO USA as auditor) passed with 31.1M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371642,"accession_number":"0001104659-22-068524","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hepion receives Nasdaq delisting notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received June 3, 2022; stock continues trading under symbol HEPA.","Non-compliance with Nasdaq Listing Rule 5550(a)(2) for minimum $1.00 bid price.","Company has 180 calendar days, until November 30, 2022, to regain compliance.","Intends to monitor bid price and consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371641,"accession_number":"0001104659-22-065556","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hepion reports positive Phase 2a AMBITION NASH data; plans three Phase 2/2b trials starting Q3 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a AMBITION NASH trial met primary endpoints: safety, tolerability, PK; no serious adverse events.","Phase 2b ASCEND-NASH planned: 336 F2/F3 biopsy-proven NASH subjects, 12-month treatment, 3 doses vs placebo.","Phase 2 ALTITUDE-NASH to assess liver function in 60 F3 NASH subjects using HepQuant SHUNT test, 4-month duration.","Phase 2a HCC trial (Simon 2-stage) to enroll up to 42 advanced HCC subjects; primary endpoint disease control rate.","Screening and enrollment for all three studies expected to begin in Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390596,"accession_number":"0001104659-22-003432","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals announces death of director Thomas Adams","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Adams, Ph.D., passed away on January 9, 2022 due to natural causes.","Dr. Adams served on Hepion's board since September 2016.","No replacement director has been announced as of the press release date.","Company expressed condolences; no other operational changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390595,"accession_number":"0001104659-22-002406","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hepion provides pipeline update: Rencofilstat Phase 2a NASH trial positive; Phase 2b and HCC trials underway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a NASH trial (AMBITION) met safety endpoints; showed ALT and Pro-C3 reductions over 28 days.","Cash $98.7M as of Sept 30, 2021; 76.2M shares outstanding.","Phase 2b NASH trial (ASCEND-NASH) to randomize 336 subjects across 75, 150, 225 mg doses for 12 months.","Phase 2a HCC trial (HEPA-RENCOFILSTAT-209) launched with Simon 2-stage design; primary endpoint disease control rate.","AI-POWR platform predicts responders; transcriptomics misclassification error <5% in Phase 2a analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390594,"accession_number":"0001104659-22-001950","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hepion's lead NASH drug gets USAN name 'rencofilstat'","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USAN Council adopted 'rencofilstat' as nonproprietary name for CRV431, Hepion's lead NASH/liver disease drug.","The name will be used in future publications, conferences, and clinical development steps.","Hepion is a clinical-stage biopharma focusing on AI-driven therapies for NASH and other liver diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408640,"accession_number":"0001104659-21-151970","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hepion Pharma gets FDA IND clearance for CRV431 in liver cancer (HCC), enabling direct Phase 2 start","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted IND for CRV431 for hepatocellular carcinoma; allows Phase 2 trial to begin without Phase 1.","CRV431 is a liver-targeting cyclophilin inhibitor; also being studied for NASH with Phase 2b ASCEND-NASH expected in 2022.","Positive Phase 2a AMBITION NASH data previously reported; CRV431 well-tolerated with all primary endpoints met.","Company highlights CRV431's oral dosing and potential anti-tumor mechanisms including immune modulation.","Expansion into HCC complements existing NASH pipeline with a single once-daily oral agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761718.86,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-21T23:59:59+00:00|408640"}